Search

Ardelyx Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.77 1.62

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.67

Max

3.77

Pagrindiniai rodikliai

By Trading Economics

Pajamos

21M

-17M

Pardavimai

26M

121M

Pelnas, tenkantis vienai akcijai

-0.07

Pelno marža

-13.833

Darbuotojai

489

EBITDA

20M

-10M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+267.39% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-254M

976M

Ankstesnė atidarymo kaina

2.15

Ankstesnė uždarymo kaina

3.77

Naujienos nuotaikos

By Acuity

67%

33%

298 / 339 reitingas Healthcare

Ardelyx Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-02 20:08; UTC

Ardelyx Inc is rising on biotechnology sector strength during Wednesday's session, despite being below its 20-day moving average and near the one-month range low.

2026-09-01 23:06; UTC

Ardelyx Inc shares are lower in after-market hours, continuing a decline since Tuesday's close. The stock remains below its 20-day moving average.

2026-08-31 20:07; UTC

Ardelyx Inc shares are lower amid broader market pressure from comments at the Jackson Hole Economic Symposium about persistent inflation and potential rate hikes.

2026-08-28 20:08; UTC

Ardelyx Inc. shares are trading roughly flat amid no specific news. The stock remains near the lower end of its one-month trading range.

2026-08-26 19:16; UTC

Ardelyx Inc. shares are higher Wednesday, recovering from an earlier dip amid notable volatility and broader market dynamics reflecting persistent inflationary pressures.

2026-08-25 20:07; UTC

Ardelyx Inc shares are gaining amid broader market trends, supported by easing Treasury yields. The stock remains below its 20-day moving average.

2026-08-21 19:16; UTC

Ardelyx Inc shares are higher today, continuing positive momentum since Thursday. No specific news was identified to explain the price movement.

2026-08-20 20:01; UTC

News

Ardelyx Inc shares are lower amid a securities investigation into its revised IBSRELA revenue guidance, which was cut to $350-$370 million.

2026-08-19 23:01; UTC

Ardelyx Inc. shares are higher in after-market trading, reflecting broader market gains. The stock remains below its 20-day moving average.

2026-08-18 23:06; UTC

Ardelyx Inc. shares are roughly flat in after-market trading. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

2026-08-17 19:26; UTC

News

Ardelyx shares are lower as Levi & Korsinsky investigates potential federal securities law violations amid reduced revenue guidance for IBSRELA.

2026-08-14 23:56; UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

2026-08-13 23:01; UTC

Ardelyx Inc. shares advanced modestly in after-market trading, though they remain significantly below the 20-day moving average and near the one-month range's lower end.

2026-08-12 23:26; UTC

Ardelyx Inc. shares were trading roughly flat in after-market hours. The stock has declined significantly over the past month amid broader market weakness.

2026-08-11 19:56; UTC

Ardelyx Inc's shares are lower today, reflecting a broader decline in the biotechnology sector. Investors monitor macroeconomic factors ahead of the Consumer Price Index report.

2026-08-10 23:56; UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

2026-08-07 23:31; UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

2026-08-06 23:31; UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

2026-08-03 19:16; UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

2026-07-31 19:16; UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

2026-07-30 23:51; UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

2026-07-22 19:31; UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

2026-07-20 19:02; UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Akcijų palyginimas

Kainos pokytis

Ardelyx Inc Prognozė

Kainos tikslas

By TipRanks

267.39% į viršų

12 mėnesių prognozė

Vidutinis 13.63 USD  267.39%

Aukščiausias 18 USD

Žemiausias 9 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ardelyx Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

8

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

298 / 339 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
help-icon Live chat